Video
27 Jan 2025

Heavy Crosslinking Due to Novel Plant Extracts – Challenge Accepted With Rxl® Ultra

Existing and upcoming trends for plant-based extracts represent a challenge for softgel manufacturers – as potential extreme crosslinking components.

  • With RXL® Ultra, GELITA re-focusses on an established, but hidden/un-noticed, solution to conquer these crosslinking challenges. As part of the RXL®-product family, the modified gelatin RXL® Ultra is the benchmark in anti-crosslinking performance for gelatin based excipients. While maintaining the known benefits in softgel production for gelatin, it provides ultimate potential to solve even extreme crosslinking and – in the end – deliver reliable products to the consumer.
  • This session will also provide insights on the regulatory background for RXL® Ultra and how to overcome challenges when used as capsule material.

  • Content provided by our supplier

    Gelita Health GmbH

    • Country/Region:
      Germany
    • On CPHI since:
      2015
    • Employees:
      1000 - 4999
    Company types
    Manufacturer/Innovator

    Other Content from Gelita Health GmbH (2)